Home Ingredients Veri-te™ Resveratrol (Evolva)
LongevityCardiovascularBone HealthCognitiveWomen's HealthMenopause Support

Veri-te™ Resveratrol (Evolva)

trans-Resveratrol (yeast-fermented, pharmaceutical-grade)
Evidence Level
Moderate
3 Clinical Trials
7 Documented Benefits
3/5 Evidence Score

Branded yeast-fermented pharmaceutical-grade trans-resveratrol from Evolva (Switzerland). Distinguishing feature: produced via fermentation rather than extracted from Japanese knotweed (Polygonum cuspidatum) — yields >98% purity with no emodin contamination (the laxative anthraquinone present in knotweed). RESHAW Trial (Howe, Wong, Thaung Zaw et al., University of Newcastle, Australia) is the longest-running resveratrol study in postmenopausal women — 12-month + 12-month crossover (n=125-129, ages 45-85) at 75 mg twice daily (150 mg/day). Improved cognitive performance and cerebrovascular responsiveness; bone density improvements (lumbar spine and femoral neck); pain perception, menopausal symptoms, and quality of life all improved. Ornstrup 2014 (PMID 25494663) — bone mineral density in obese men.

Studied Dose RESHAW PIVOTAL: 75 mg trans-resveratrol BID = 150 mg/day × 12-24 months in postmenopausal women. STANDARD: 100-200 mg/day with light fat. 24-month RESHAW provides longest available safety data. Pregnancy: avoid (theoretical estrogenic effects).
Active Compound trans-Resveratrol (yeast-fermented pharmaceutical-grade, ≥98% purity). Stilbene phytoalexin. Distinct from Japanese knotweed-derived resveratrol (which contains other compounds like emodin)

Benefits

Cognitive performance + cerebrovascular function in postmenopausal women (RESHAW)

RESHAW (Resveratrol Supporting Healthy Ageing in Women) Trial — University of Newcastle, Australia (Howe P, Wong R, Thaung Zaw JJ et al.). 12-month phase 1 in 129 postmenopausal women aged 45-85 at 75 mg twice daily (150 mg/day). Improved cognitive performance and reduced decline in cerebrovascular responsiveness (Nutrients 2020 publication). Pivotal long-duration RCT in a high-priority population for healthspan interventions.

Supported by Trial 1

Bone mineral density improvements (RESHAW bone arm)

24-month crossover bone arm (n=125). Improved bone density in lumbar spine and femoral neck, with 7.2% reduction in plasma CTX-I bone resorption marker. Effect was subgroup-dependent — those with higher baseline bone resorption benefited more. Important nuance: the intervention works best in those with active bone loss rather than uniformly across all postmenopausal women.

Supported by Trial 2

Bone mineral density obese men (Ornstrup 2014, PMID 25494663)

Ornstrup MJ et al. 2014 (PMID 25494663, J Clin Endocrinol Metab). Bone mineral density trial in obese men. Replicates the bone effects in a different population (obese men vs postmenopausal women) — supports the bone metabolism mechanism beyond purely estrogen-related pathways.

Supported by Trial 3

Pain, menopausal symptoms, and quality of life (RESHAW final publication)

RESHAW final publication (J North American Menopause Society) — improved pain perception, menopausal symptoms, and overall well-being. Quality-of-life endpoints in a population where pharmacological options are limited and HRT carries risks.

Supported by Trial 2

Blood pressure improvements (Wong et al.)

Wong et al. — blood pressure trial in 19 overweight/obese hypertensive subjects. Cardiovascular adjunct evidence consistent with the endothelial NO mechanism.

Supported by Trial 1, Trial 3

Pharmaceutical-grade yeast fermentation purity

Distinguishing manufacturing advantages: >98% trans-resveratrol purity; NO emodin (the laxative anthraquinone present in knotweed extracts); sustainable production independent of wild knotweed harvesting; consistent batch-to-batch potency suitable for pharmaceutical research; GMP-compliant manufacturing. Used by Cincinnati University and other academic research applications.

Supported by Trial 1

Endothelial function in postmenopausal women

Cerebrovascular responsiveness improvements in RESHAW reflect the broader endothelial function effect — underlying both the cognitive and cardiovascular benefits via shared NO-mediated vascular mechanisms.

Supported by Trial 1

Mechanism of action

1

SIRT1 activation (longevity pathway)

Resveratrol activates sirtuin 1 (SIRT1) — the central NAD-dependent deacetylase implicated in caloric restriction mimicry and longevity pathways. Foundational mechanism rationale for the healthspan applications.

2

AMPK activation

AMP-activated protein kinase activation — energy-sensing pathway shared with metformin and exercise. Mechanistic complement to SIRT1 in the metabolic and longevity framework.

3

Endothelial NO production enhancement

Endothelial nitric oxide production enhancement underlies both the cardiovascular benefits and the cerebrovascular responsiveness improvements documented in RESHAW.

4

Estrogen receptor modulation

Mild phytoestrogenic activity via estrogen receptor binding — explains the menopausal symptom benefits and bone effects in postmenopausal women. Pregnancy avoidance recommendation reflects this mechanism.

5

Bone metabolism modulation

Reduces bone resorption markers (CTX-I) and increases bone alkaline phosphatase. Multi-target bone metabolism effect supporting the BMD outcomes in RESHAW and Ornstrup 2014.

6

NF-κB anti-inflammatory pathway suppression

NF-κB pathway suppression contributes to the broader anti-inflammatory and metabolic effects.

7

Antioxidant + mitochondrial biogenesis

Antioxidant activity plus mitochondrial biogenesis via PGC-1α — supports the longevity and metabolic mechanisms.

Clinical trials

1
RESHAW — Veri-te™ Postmenopausal Cognitive + Cerebrovascular RCT (PIVOTAL)

RESHAW (Resveratrol Supporting Healthy Ageing in Women) Trial — University of Newcastle, Australia. 12-month phase 1 in 129 postmenopausal women aged 45-85 at 75 mg twice daily (150 mg/day). Improved cognitive performance and reduced decline in cerebrovascular responsiveness (Nutrients 2020). Pivotal long-duration RCT supporting cognitive aging adjunct positioning.

2
RESHAW Bone Mineral Density Arm — Veri-te™ 24-Month Bone RCT

24-month crossover bone arm (n=125). Improved bone density in lumbar spine and femoral neck. 7.2% reduction in plasma CTX-I bone resorption marker. Subgroup-dependent: higher baseline bone resorption benefited more. Final publication (J North American Menopause Society): improved pain, menopausal symptoms, well-being.

3
Ornstrup 2014 — Resveratrol Bone Mineral Density Obese Men (PMID 25494663)

Ornstrup MJ et al. 2014 (PMID 25494663, J Clin Endocrinol Metab). Bone mineral density trial in obese men. Replicates RESHAW bone effects in a different population, supporting bone metabolism mechanism beyond estrogen-related pathways.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated; 24-month RESHAW trial confirms long-term safety.
GI upset (occasional, especially at high doses).
Diarrhea (rare, typically at higher doses).
Mild allergic reactions (rare).
Pregnancy/lactation: AVOID (theoretical estrogenic effects + limited data).
Estrogen-sensitive conditions: caution (mild phytoestrogenic activity).
Long-term safety: 24-month RESHAW trial supports favorable profile.
Yeast-fermented: NO emodin contamination (vs Japanese knotweed extracts) — practical advantage.

Important Drug interactions

Anticoagulants (warfarin, DOACs): theoretical antiplatelet effects — monitor closely.
CYP3A4 substrates: theoretical interactions (statins, immunosuppressants, etc.).
Tamoxifen, hormone-sensitive treatments: caution due to mild estrogenic activity.
Antihypertensives: theoretical mild additive effects.
Antidiabetic medications: theoretical compatible/additive glucose effects.
Most medications: well-tolerated combination profile at typical doses.

More Longevity Ingredients

Cognitive
Longvida® Optimized Curcumin (Verdure Sciences)
Longvida® is a PATENTED CURCUMIN EXTRACT developed by Verdure Sciences using SLCP™ (Solid…
Energy
Nicotinamide Riboside (Niagen®)
Nicotinamide Riboside (NR) is a form of vitamin B3 and a direct precursor to NAD+, the coe…
Muscle & Recovery
Urolithin A (Mitopure® — Mitophagy Activator)
Urolithin A (UA) is a gut microbiome-derived metabolite produced from ellagitannins (found…
Cardiovascular
Ubiquinol (Reduced CoQ10)
Ubiquinol is the REDUCED, electron-rich form of CoQ10 — distinct from ubiquinone (oxidized…

Frequently asked questions about Veri-te™ Resveratrol (Evolva)

What is the recommended dosage of Veri-te™ Resveratrol (Evolva)?

The clinically studied dose for Veri-te™ Resveratrol (Evolva) is RESHAW PIVOTAL: 75 mg trans-resveratrol BID = 150 mg/day × 12-24 months in postmenopausal women. STANDARD: 100-200 mg/day with light fat. 24-month RESHAW provides longest available safety data. Pregnancy: avoid (theoretical estrogenic effects).. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is Veri-te™ Resveratrol (Evolva) used for?

Veri-te™ Resveratrol (Evolva) is studied for cognitive performance + cerebrovascular function in postmenopausal women (reshaw), bone mineral density improvements (reshaw bone arm), bone mineral density obese men (ornstrup 2014, pmid 25494663). RESHAW (Resveratrol Supporting Healthy Ageing in Women) Trial — University of Newcastle, Australia (Howe P, Wong R, Thaung Zaw JJ et al.). 12-month phase 1 in 129 postmenopausal women aged 45-85 at 75 mg twice daily (150 mg/day).

Are there side effects from taking Veri-te™ Resveratrol (Evolva)?

Reported potential side effects may include: Generally well-tolerated; 24-month RESHAW trial confirms long-term safety. GI upset (occasional, especially at high doses). Always consult a healthcare provider before starting any new supplement, especially if you have underlying conditions or take medications.

Does Veri-te™ Resveratrol (Evolva) interact with medications?

Known drug interactions may include: Anticoagulants (warfarin, DOACs): theoretical antiplatelet effects — monitor closely. CYP3A4 substrates: theoretical interactions (statins, immunosuppressants, etc.). Consult a pharmacist or healthcare provider if you take prescription medications.

Is Veri-te™ Resveratrol (Evolva) good for longevity?

Yes, Veri-te™ Resveratrol (Evolva) is researched for Longevity support. RESHAW (Resveratrol Supporting Healthy Ageing in Women) Trial — University of Newcastle, Australia (Howe P, Wong R, Thaung Zaw JJ et al.). 12-month phase 1 in 129 postmenopausal women aged 45-85 at 75 mg twice daily (150 mg/day).